We are Healthy
U.S.

FDA Approved First Treatment for Symptomatic Dermographism

Adults with chronic hives unresponsive to antihistamines may soon have a new, FDA-approved prescription option.

Updated on Oct. 7, 2026 in Allergies

Bold vector editorial illustration of a stylized, minimalist medical capsule in coral and teal against a cream background, representing clinical progress.
The FDA has approved Rhapsido as the first prescription treatment for adults with symptomatic dermographism who remain unresponsive to standard antihistamines. AI Illustration. Upload story photo >

Live Poll

Do you believe new pharmaceutical treatments for chronic skin conditions will improve your overall quality of life?

The FDA has officially approved Rhapsido as the first medication specifically designed to treat adults suffering from symptomatic dermographism. This approval offers a new path for patients who have not achieved symptom control using standard H1 antihistamines.

Why it matters

The approval addresses a critical treatment gap for patients whose chronic hives persist despite traditional antihistamine therapy. Because symptomatic dermographism and chronic spontaneous urticaria make up over 90% of adult chronic hives cases, this option provides a vital new resource for widespread patient needs.

In the Phase 3 RemIND trial, 29.3% of participants treated with Rhapsido achieved complete hive clearance by the 12-week mark, compared to 14.0% in the placebo group. The safety profile remained consistent throughout the study period of up to 24 weeks.

The players

Novartis

A pharmaceutical company specializing in immunology and neurology that developed Rhapsido.

FDA

The federal agency responsible for regulating and approving medical treatments in the United States.

The details

Rhapsido is now the only prescription medication approved to treat both symptomatic dermographism and chronic spontaneous urticaria in the United States. The drug is intended for patients who do not reach control with H1 antihistamines alone. In the trial, some participants began to observe clinical results as early as week two of the study.

Timeline

  1. The FDA approved Rhapsido on Wednesday.

  2. Some patients began seeing clinical results by the second week of treatment.

  3. Trial participants reached the 12-week mark for complete hive clearance data.

  4. Clinical trials demonstrated a consistent safety profile for up to 24 weeks.

Health Landscape

This approval represents a significant shift in the treatment of chronic hives, moving the standard of care beyond traditional H1 antihistamines. It follows the data established by the RemIND trial, marking a departure from previous protocols for managing chronic urticaria.

If you have been managing symptomatic dermographism without success on antihistamines, this new approval is a significant topic to bring up with your doctor. Discuss whether this prescription medication aligns with your specific clinical history and current care plan.

The takeaway

Rhapsido offers a new therapeutic pathway for adults who have struggled to manage chronic hives with traditional antihistamines. Patients should consult their physician to evaluate if this new treatment option is appropriate for their specific case of symptomatic dermographism.

Further reading

Learn more about the latest breakthroughs in managing Allergies.

Live Poll

Do you believe new pharmaceutical treatments for chronic skin conditions will improve your overall quality of life?